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Abstract
Anticonvulsants such as phenytoin, phenobarbital, topi-
ramate, carbamazepine and valproate due to their ben-
eficial effects and economic benefits in compare to new 
drugs are used more but these drugs are not harmless 
and sometimes had dangerous, safe and reversible side 
effects. Reduction of the nervous conduction velocity 
(NCV) is the common side effect of these drugs and it is 
of clinically importance if it is severe especially in treat-
ed children. Therefore, it is necessary to evaluate and 
compare the effect of each drug on NCV. The aim of this 
study was to investigate the effects of antiepileptic drugs 
on NCV. In this quasi-experimental study, 125 children 
with seizure were randomly selected and divided into six 
equal size groups which received phenytoin, phenobarbi-
tal, topiramate, valproate, carbamazepine and one group 
as control which no received anti-epileptic drug. Sensory 
and motor neural conduction velocity were measured and 
recorded for all children in groups. Collected data were 
analyzed by statistical methods in SPSS version 19. All 
of anticonvulsants were reduced the NCV in children but 
among all drugs, phenobarbital and phenytoin had the 
least and most impact on the NCV. The changes in NCV 
were not related to the age and gender of children. Re-
sults showed that the anticonvulsants had similar impact 
on NCV in generally but future studies are recommended 
by considering the other effective variables on response 
to drug.
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Introduction
About one percent of the world’s population had 
epilepsy. Epilepsy attacks are the second most com-
mon neurological disorder after stroke. Today standard 
treatments have managed to control nearly 80% of pa-
tients. Seizures are short term episodes as a result of 
abnormal discharge of brain neurons. Various causes 
such as infection, neoplasm or trauma may be involved 
in these attacks. Epilepsy is one of the most common 
diagnoses seen by pediatric neurologists. One percent 
to two percent of the pediatric population has epilepsy 
[1]. Almost 4-10% of children experience at least one 
seizure. The prevalence of epilepsy in children is about 
1-2%. The goal of treatment in children is to maintain 
optimal functional status. About in 60% of children, the 
seizure was controlled by using an appropriate prima-
ry drug and the results are satisfactory. We know that 
while 80% of people with epilepsy live in low- and mid-
dle-income countries, most of them do not have access 
to treatment [2]. Seizure is one of the most common 
diseases in children age group which was controlled by 
the availability of anticonvulsants, and due to the im-
pact of anticonvulsants which act through the action on 
the membrane potential, it seems that these medica-
tions can affect the NCV [3-6]. Of course, in the poison-
ing with some medications such as phenytoin, the NCV 
has decreased. On the other one, one of the effective 
factors on the NCV was ambient temperature while 
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Ethical approve
This study ethical approves by ethical committee of 
Ardabil University of Medical Sciences and registered 
by code REC.ARUMS.1397.675. In this study parents of 
children were informed and the consent form was com-
pleted for them.
Results
The average age of children was 5.5 ± 2.9 years in 
range of 2 to 11. Of all children, 68 (45.4%) were boy 
and 82 (55.6%) were girls. All of used drugs compared 
to the control group, significantly reduced sensory and 
motor NCV of upper and lower limbs nerves.
The phenytoin as an anti-seizure drug compared to 
the control group significantly reduced the motor and 
sensory NCV in the upper and lower limbs for nerves 
Median, Sural and Peroneal but the difference between 
phenytoin at baseline and control in Ulnar nerve wasn’t 
significant (Table 1).
The phenobarbital as an anti-seizure drug compared 
to the control group significantly reduced the motor and 
sensory NCV in the upper and lower limbs for nerves 
Median, Sural and Peroneal but the difference between 
phenobarbital at baseline and control in Ulnar nerve 
wasn’t significant (Table 2).
The topiramate as an anti-seizure drug compared to 
the control group significantly reduced the motor and 
sensory NCV in the upper and lower limbs for nerves 
Median, Sural, Ulnar and Peroneal (Table 3).
The sodium-valproate as an anti-seizure drug com-
pared to the control group significantly reduced the mo-
tor and sensory NCV in the upper and lower limbs for 
nerves Median, Sural, Ulnar and Peroneal (Table 4).
some anticonvulsants can increase fever in body [7-10]. 
Also, consumers of anticonvulsants in neurological ex-
aminations show declining deep reflexes [11].
Anticonvulsants such as phenytoin, phenobarbital, 
topiramate, carbamazepine and valproate due to their 
beneficial effects and economic benefits in compare to 
new drugs are used more but these drugs are not harm-
less and sometimes had dangerous, safe and reversible 
side effects. Reduction of the nervous conduction ve-
locity (NCV) is the common side effect of these drugs 
and it is of clinically importance if it is severe especially 
in children and need for more attention of physician in 
clinically using of these drugs. The aim of this study was 
to investigate the effects of antiepileptic drugs on NCV.
Materials and Methods
This was a quasi-experimental study. In this study, 
children aged 2-15 years with one of generalized or 
partial seizures requiring anticonvulsant drugs (Phe-
nytoin, phenobarbital, Topiramate, carbamazepine, so-
dium valproate) selected and randomly divided into 5 
groups each with 25 patients and each group received 
a drug. We also selected a control group without any 
drug use. Children were excluded from the study if they 
had any disruptive factors which affect NCV. At base line 
an NCV was performed for all groups. In this study the 
NCV were measured in the upper limbs in the median 
and ulna nerves and in the lower limbs in Peroneal and 
sural nerves by the EMG-NCV, Micromed device (made 
in Italy) and 6 months later these measurements was 
performed again and the necessary data were collected. 
After collecting NCV information along with age, sex and 
type of drug, data were analyzed by statistical methods 
in SPSS version 19.
Table 1: Compare the mean of NCV in treated patients with phenytoin by type of nerve.
 Type of nerves Drugs Mean P - value 
Median Phenytoin in Baseline 52 0.009
Control 58.7
Median Phenytoin in baseline 52 0.016
Phenytoin 6 month late 51.6
Ulnar Phenytoin in Baseline 51.2 0.058
Control 50.8
Ulnar Phenytoin in baseline 51.2 0.011
Phenytoin 6 month late 50.6
Sural Phenytoin in Baseline 47.7 0.002
Control 50.6
Sural Phenytoin in baseline 47.7 0.026
Phenytoin 6 month late 47.2
Peroneal Phenytoin in Baseline 43.8 0.002
Control 46.4
Peroneal Phenytoin in baseline 43.8 0.009
Phenytoin 6 month late 42.9
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Table 2: Compare the mean of NCV in treated patients with phenobarbital by type of nerves.
 Type of nerves Drugs Mean P - value 
Median Phenobarbital in baseline 56 0.038
Control 58.7
Median phenobarbital in baseline 56 0.065
phenobarbital six month late 55.4
Ulnar phenobarbital in baseline 54.2 0.06
Control 50.8
Ulnar phenobarbital in baseline 54.2 0.057
Phenobarbital six month late 53.2
Sural phenobarbital in Baseline 45.2 0.001
Control 50.6
Sural phenobarbital in baseline 45.2 0.06
Phenobarbital six month late 43.8
Peroneal phenobarbital in baseline 42.8 0.011
Control 46.4
Peroneal phenobarbital in baseline 42.8 0.053
Phenobarbital six month late 41.2
Table 3: Compare the mean of NCV in treated patients with topiramate by type of nerves.
 Type of nerves Drugs Mean P - value 
Median topiramate in baseline 52.3 0.003
Control 58.7
Median topiramate in baseline 52.3 0.053
topiramate six month late 52.4
Ulnar topiramate in baseline 50.2 0.0024
Control 50.8
Ulnar topiramate in baseline 50.2 0.061
topiramate six month late 50.1
Sural topiramate in Baseline 46.7 0.003
Control 50.6
Sural topiramate in baseline 46.7 0.298
topiramate six month late 46.2
Peroneal topiramate in baseline 43.8 0.0051
Control 46.4
Peroneal topiramate in baseline 43.8 0.13
topiramate six month late 43.02
Table 4: Compare the mean of NCV in treated patients with sodium valproate by type of nerves.
Type of nerves Drugs Mean P -value
Median sodium valproate in baseline 53.4 0.003
Control 58.7
Median sodium valproate in baseline 53.4 0.072
sodium valproate six month late 53.3
Ulnar sodium valproate in baseline 50.1 0.0002
Control 50.8
Ulnar sodium valproate in baseline 50.1 0.068
sodium valproate six month late 50.08
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and peroneal nerves [3]. A study by Danner, et al. found 
that carbamazepine as an anti-seizure drug more than 
phenytoin reduced the NCV which was similar to our 
study results [12]. According to the results of Freeman, 
et al. research on the subject of polyneuropathy treat-
ment, the mean of decrease in NCV for placebo was 
higher than that of topiramate. Secondary measure-
ments showed that the NCV was not reduced for treat-
ed patients with topiramate [13]. Swift, et al. showed 
that there was no relationship between phenobarbital 
or phenytoin levels in blood and the duration of their 
use and abnormality of electrical findings as well as en-
vironmental neuropathy [14]. According to research by 
Chokroverty, et al. the NCV in the posterior tibial nerve 
was significantly reduced in patients who had been treat-
ed with phenytoin for more than 10 years or those who 
had a drug level of more than 20 mug/ml in their blood 
[15]. In a study by Danner, et al. the results show that 
carbamazepine reduce the NCV after 4 weeks treatment 
[16]. The result of Danner, et al. study showed a signif-
icant decrease in NCV in seizure patients who receiving 
anticonvulsants compared to the control group which 
was similar to our study results [17]. In research by Cas-
tro, et al. the NCV in patients receiving anticonvulsants 
is significantly reduced compared to the control group 
The carbamazepine as an anti-seizure drug com-
pared to the control group significantly reduced the 
motor and sensory NCV in the upper and lower limbs 
for nerves Median, Sural, Ulnar and Peroneal (Table 5).
The effect of anticonvulsants on the motor and sen-
sory NCV of the upper and lower limbs was not related 
to the gender and age of children.
By comparing the effect of phenytoin and phenobar-
bital on NCV, we seen that in the median nerve phe-
nytoin significantly reduced the NCV more than phe-
nobarbital. Comparing the effect of phenobarbital and 
topiramate on NCV, we see that topiramate significantly 
reduced the NCV in the median nerve more than phe-
nobarbital. Comparing the effect of phenobarbital and 
valproate on NCV, we see that valproate sodium sig-
nificantly reduced the NCV in median nerve more than 
phenobarbital. Comparing the effect of phenobarbital 
and carbamazepine on NCV we see that carbamazepine 
significantly reduced the NCV in the median nerve more 
than phenobarbital.
Discussion
In a similar study in 1990, Krause, et al. suggested 
that anticonvulsants reduced the NCV in the median 
Sural sodium valproate in Baseline 47.5 0.004
Control 50.6
Sural sodium valproate in baseline 47.5 0.1
sodium valproate six month late 47.8
Peroneal sodium valproate in baseline 46.8 0.046
Control 46.4
Peroneal sodium valproate in baseline 46.8 0.095
sodium valproate six month late 46.75
Table 5: Compare the mean of NCV in treated patients with Carbamazepine by type of nerves.
Type of nerves Drugs Mean P - value
Median Carbamazepine in baseline 52.4 0.004
Control 58.7
Median Carbamazepine in baseline 52.4 0.028
Carbamazepine six month late 50.6
Ulnar Carbamazepine in baseline 50.6 0.0039
Control 50.8
Ulnar Carbamazepine in baseline 50.6 0.041
Carbamazepine six month late 48.7
Sural Carbamazepine in Baseline 48.1 0.006
Control 50.6
Sural Carbamazepine in baseline 50.6 0.03
Carbamazepine six month late 48.04
Peroneal Carbamazepine in baseline 46.5 0.0286
Control 46.4
Peroneal Carbamazepine in baseline 46.5 0.037
Carbamazepine six month late 46.3
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decreased NCV is higher in phenytoin than carbamaz-
epine [27]. According to Ay, et al. study, both carba-
mazepine and valproate sodium cause environmental 
neuropathy and there was no significant difference in 
the side effects of neuropathy between two drugs [28]. 
In this study similar to previous studies, phenobarbital 
decreases the rate of NCV less than other drugs and 
phenytoin more than other drugs reduced the NCV. But 
differences in the results of the effects of carbamaze-
pine can be due to the variability of its blood level and 
previous studies have been carried out to evaluate the 
blood levels of drugs and starting an anticonvulsant 
medication as a first line of treatment may also be in-
volved. Also the racial and age differences in response 
to drugs should not be over looked and this topic due to 
neurological complications especially in children is very 
important.
Conclusions
All of the anticonvulsants used in the study, re-
duced the motor and sensory NCV of the upper and 
lower extremities of the nerves. The gender of pa-
tients did not affect the sensory and motor NCV of 
the seizure patients treated with anticonvulsants. 
There was no significant correlation between the age 
of patients and their sensory NCV when taking anti-
convulsant drugs. Anticonvulsant medications were 
similar in the reduction of NCV but among them phe-
nobarbital was less effective than other drugs and 
phenytoin reduced NCV more than others. It is sug-
gested that studies be conducted on the basis of the 
blood levels of drugs in the future.
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